Viking Therapeutics plans USD 200 million convertible senior notes offering due 2032

By Public Technologies
  • Viking Therapeutics launched a public offering of USD 200 million convertible senior notes due 2032.
  • Underwriters hold a 30-day option to buy up to an additional USD 30 million of the notes for over-allotments.
  • Notes to mature Oct. 15, 2032; senior unsecured; interest payable semi-annually; conversion settled in cash, shares, or both.
  • Redemption allowed from Oct. 22, 2029 if shares trade above 130% of the conversion price for a specified period.
  • Proceeds earmarked for development and commercialization of VK2735, advancement of VK3019, working capital, and general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609231632PR_NEWS_USPR_____LA55581) on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.